These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
497 related articles for article (PubMed ID: 27012991)
1. Comparison of the effects of levocetirizine and losartan on diabetic nephropathy and vascular dysfunction in streptozotocin-induced diabetic rats. Anbar HS; Shehatou GS; Suddek GM; Gameil NM Eur J Pharmacol; 2016 Jun; 780():82-92. PubMed ID: 27012991 [TBL] [Abstract][Full Text] [Related]
2. Combination therapy with losartan and L-carnitine protects against endothelial dysfunction of streptozotocin-induced diabetic rats. Sleem M; Taye A; El-Moselhy MA; Mangoura SA Eur J Pharmacol; 2014 Dec; 744():10-7. PubMed ID: 25281836 [TBL] [Abstract][Full Text] [Related]
3. Huangkui capsule attenuates renal fibrosis in diabetic nephropathy rats through regulating oxidative stress and p38MAPK/Akt pathways, compared to α-lipoic acid. Mao ZM; Shen SM; Wan YG; Sun W; Chen HL; Huang MM; Yang JJ; Wu W; Tang HT; Tang RM J Ethnopharmacol; 2015 Sep; 173():256-65. PubMed ID: 26226437 [TBL] [Abstract][Full Text] [Related]
4. Rupatadine, a dual antagonist of histamine and platelet-activating factor (PAF), attenuates experimentally induced diabetic nephropathy in rats. Hafez HM; Abdel-Hakeem EA; Hassanein H Naunyn Schmiedebergs Arch Pharmacol; 2020 Aug; 393(8):1487-1500. PubMed ID: 32200462 [TBL] [Abstract][Full Text] [Related]
5. Effects of angiotensin receptor blocker on oxidative stress and cardio-renal function in streptozotocin-induced diabetic rats. Arozal W; Watanabe K; Veeraveedu PT; Ma M; Thandavarayan RA; Suzuki K; Tachikawa H; Kodama M; Aizawa Y Biol Pharm Bull; 2009 Aug; 32(8):1411-6. PubMed ID: 19652382 [TBL] [Abstract][Full Text] [Related]
6. Protective effects of oxymatrine on experimental diabetic nephropathy. Guo C; Han F; Zhang C; Xiao W; Yang Z Planta Med; 2014 Mar; 80(4):269-76. PubMed ID: 24535719 [TBL] [Abstract][Full Text] [Related]
7. Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. Qin J; Zhang Z; Liu J; Sun L; Hu L; Cooper ME; Cao Z Kidney Int; 2003 Aug; 64(2):565-71. PubMed ID: 12846751 [TBL] [Abstract][Full Text] [Related]
8. Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK-NF-κB-TNF-α and TGF-β1-MAPK-fibronectin pathways. Malik S; Suchal K; Khan SI; Bhatia J; Kishore K; Dinda AK; Arya DS Am J Physiol Renal Physiol; 2017 Aug; 313(2):F414-F422. PubMed ID: 28566504 [TBL] [Abstract][Full Text] [Related]
9. BAY 11-7082 ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated oxidative stress and renal inflammation via NF-κB pathway. Kolati SR; Kasala ER; Bodduluru LN; Mahareddy JR; Uppulapu SK; Gogoi R; Barua CC; Lahkar M Environ Toxicol Pharmacol; 2015 Mar; 39(2):690-9. PubMed ID: 25704036 [TBL] [Abstract][Full Text] [Related]
10. Effect of catalpol on diabetic nephropathy in rats. Dong Z; Chen CX Phytomedicine; 2013 Aug; 20(11):1023-9. PubMed ID: 23746755 [TBL] [Abstract][Full Text] [Related]
11. Anti-diabetic and renoprotective effects of aliskiren in streptozotocin-induced diabetic nephropathy in female rats. Mahfoz AM; El-Latif HA; Ahmed LA; Hassanein NM; Shoka AA Naunyn Schmiedebergs Arch Pharmacol; 2016 Dec; 389(12):1315-1324. PubMed ID: 27612855 [TBL] [Abstract][Full Text] [Related]
12. Tropisetron ameliorates early diabetic nephropathy in streptozotocin-induced diabetic rats. Barzegar-Fallah A; Alimoradi H; Asadi F; Dehpour AR; Asgari M; Shafiei M Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):361-8. PubMed ID: 25676798 [TBL] [Abstract][Full Text] [Related]
13. Attenuation of renoinflammatory cascade in experimental model of diabetic nephropathy by sesamol. Kuhad A; Sachdeva AK; Chopra K J Agric Food Chem; 2009 Jul; 57(14):6123-8. PubMed ID: 19601660 [TBL] [Abstract][Full Text] [Related]
14. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat. Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251 [TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of rosiglitazone and losartan combination in diabetic rats. Ateyya H; Nader MA; El-Sherbeeny NA Can J Physiol Pharmacol; 2018 Mar; 96(3):215-220. PubMed ID: 28892640 [TBL] [Abstract][Full Text] [Related]
16. Protective effects of allicin on streptozotocin-induced diabetic nephropathy in rats. Huang H; Jiang Y; Mao G; Yuan F; Zheng H; Ruan Y; Wu T J Sci Food Agric; 2017 Mar; 97(4):1359-1366. PubMed ID: 27363537 [TBL] [Abstract][Full Text] [Related]
17. Protective effect of Icariin on the early stage of experimental diabetic nephropathy induced by streptozotocin via modulating transforming growth factor β1 and type IV collagen expression in rats. Qi MY; Kai-Chen ; Liu HR; Su YH; Yu SQ J Ethnopharmacol; 2011 Dec; 138(3):731-6. PubMed ID: 22027446 [TBL] [Abstract][Full Text] [Related]
18. trans-Anethole attenuated renal injury and reduced expressions of angiotensin II receptor (AT1R) and TGF-β in streptozotocin-induced diabetic rats. Samadi-Noshahr Z; Ebrahimzadeh-Bideskan A; Hadjzadeh MA; Shafei MN; Salmani H; Hosseinian S; Khajavi-Rad A Biochimie; 2021 Jun; 185():117-127. PubMed ID: 33771655 [TBL] [Abstract][Full Text] [Related]
19. Danshen injection ameliorates STZ-induced diabetic nephropathy in association with suppression of oxidative stress, pro-inflammatory factors and fibrosis. Xu L; Shen P; Bi Y; Chen J; Xiao Z; Zhang X; Wang Z Int Immunopharmacol; 2016 Sep; 38():385-94. PubMed ID: 27355131 [TBL] [Abstract][Full Text] [Related]
20. Gallic acid attenuates type I diabetic nephropathy in rats. Garud MS; Kulkarni YA Chem Biol Interact; 2018 Feb; 282():69-76. PubMed ID: 29331653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]